Vipshop Holdings Ltd - ADR vs Viatris Inc — how do they compare? Vipshop Holdings Ltd - ADR trades at $12.98 (market cap $6.05B), while Viatris Inc trades at $17.26 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 3.3× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays the higher dividend (4.87%). Which is the better fit depends on your goals — on Pluang, investors hold Vipshop Holdings Ltd - ADR for 49 Days and Viatris Inc for 57 Days on average.
| VIPS | VTRS | |
|---|---|---|
Market Cap | $6.05B | $20.03B |
Volume | 3,719,230 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $20.29 | $18.27 |
52-Week Low | $12.09 | $9.74 |
Typical Hold Time | 49 Days | 57 Days |
Enterprise Value | $2.87B | $32.15B |
Dividend Yield | 4.87% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
Vipshop Holdings trades at $12.77, showing modest daily gains of 0.16%. The stock presents compelling valuation metrics with a P/E of 4.1 and P/S of 0.4, trading below book value. Recent earnings show mixed performance with Q2 2026 missing expectations, though profitability remains strong with 9.82% net margins. Technical indicators show a bullish overall signal while oscillators remain neutral, with key support at $12.
The investment case centers on deep valuation discounts and strong profitability metrics, though revenue stagnation and consumer headwinds present challenges. Analyst consensus targets $16.17, offering 27% upside potential. Key risks include Chinese consumer sentiment weakness and competitive pressures in the off-price retail sector.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →